title: [Treatment of hyperprolactinemic anovulation with the dopamin-agonist quinagolide].
abstract: Quinagolide has a strong dopaminerg activity, suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic anovulation. The aim of our study was to investigate the effectiveness of quinagolide in the treatment of 16 hyperprolactinemic patients. The clinical diagnosis was functional hyperprolactinemia in 13 patients, microprolactinoma in 2 and empty sella syndrome in 1. The drug was administered orally and initially daily dose was 0.025 mg for the first three days, 0.050 mg for the next three days and 0.075 mg for the following 6 months. The serum prolactin level was measured monthly before pregnancy, three monthly during the pregnancy and six weeks after delivery. Serum prolactin levels decreased in most of the patients during the first month and only in one case remained in the pathological range after six months quinagolide++ treatment. Prolactin secretion changed (mean and range) from 3120 (780-5790) mU/l to 370 (84-1076) mU/l. Out of 16 hyperprolactinemic patients nine women were infertile. During quinagolide treatment 5 pregnancies occurred. In conclusion, our results show that quinagolide has a good efficacy on regulation of prolactin secretion and it is a well tolerated dopamin-agonist drug.
authors.affiliation: Szegedi Tudományegyetem, Altalános Orvostudományi Kar, Szent-Györgyi Albert Orvos- és Gyógyszerésztudományi Centrum Szülészeti és Nógyógyászati Klinika.
authors.forename: S
authors.initials: S
authors.lastname: Koloszár
authors.forename: A
authors.initials: A
authors.lastname: Keresztúri
authors.forename: L
authors.initials: L
authors.lastname: Kovács
mesh_terms: D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D000858:Anovulation / Q000188:drug therapy* / Q000209:etiology; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004652:Empty Sella Syndrome / Q000150:complications; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology; D010911:Pituitary Neoplasms / Q000150:complications; D049590:Postpartum Period / Q000097:blood; D011247:Pregnancy / Q000097:blood; D011388:Prolactin / Q000187:drug effects* / Q000378:metabolism*; D015175:Prolactinoma / Q000150:complications; D016896:Treatment Outcome
chemical_list: D000634:Aminoquinolines; D018491:Dopamine Agonists; C046650:quinagolide; D011388:Prolactin